Imatinib Mesylate Tablet, Film Coated
Product Images NDC 67877-633

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 67877-633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib-bottle-100mg (Imatinib Bottle 100mg)

Label for Imatinib Mesylate Tablets 100 mg, film-coated oral tablets. The label indicates 90 tablets per container with Rx only designation. The product is distributed by Ascend Laboratories, LLC, Parsippany, NJ, and manufactured by Shilpa Medicare Limited, India. Storage and dosage directions are provided, along with the NDC 67877-633-90 and a barcode.*

FDA Label Image

Imatinib-bottle-400mg (Imatinib Bottle 400mg)

Label for Imatinib Mesylate 400 mg tablets by Ascend Laboratories, LLC. The label states it contains 30 film-coated tablets for oral use. It includes storage instructions, manufacturer (Shilpa Medicare Limited, India), distributor information, and a barcode. The label highlights 'Rx Only' and the NDC 67877-634-30.*

FDA Label Image

Imatinib-fig1 (Imatinib Fig1)

A line chart titled 'Progression Free Survival (ITT Principle)' comparing the percentage of patients without progression over time (in months since randomization) between Imatinib mesylate and IFN+Ara-C treatments. The chart shows two survival curves, a solid line for Imatinib mesylate arm and a dashed line for IFN+Ara-C arm, with Imatinib mesylate maintaining a higher progression-free survival percentage over 72 months.*

FDA Label Image

Imatinib-fig2 (Imatinib Fig2)

A line graph titled 'Time to Progression to AP or BC (ITT Principle)' comparing the percentage without progression to AP or BC over months since randomization between two groups: Imatinib mesylate arm (solid line) and IFN + Ara-C arm (dashed line). The vertical axis shows percentage without progression, while the horizontal axis shows months up to 72. The chart includes patient counts with progression, censored data, and hazard ratio details for imatinib mesylate versus IFN + Ara-C.*

FDA Label Image

Imatinib-struc (Imatinib Struc)

Chemical structure of imatinib mesylate showing its molecular framework with aromatic rings, nitrogen atoms, and a mesylate group (CH3SO3H) denoted on the right side of the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.